You can buy or sell NAVB and other stocks, options, ETFs, and crypto commission-free!
Navidea Biopharmaceuticals, Inc. engages in the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through the following segments: Diagnostics, Therapeutics, and Corporate. Read More The company was founded in 1983 and is headquartered in Dublin, OH.
52 Week High
52 Week Low
Stock Price, News, & Analysis for Navidea Biopharmaceuticals
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages; and NAV4694, a fluorine-18 labeled positron emission tomography imaging agent for use as an aid in the imaging and evaluation of ...
Navidea Biopharmaceuticals Schedules Fourth Quarter 2018 Earnings Conference Call and Business Update
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American:NAVB) (“Navidea” or “the Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will host a conference call on Thursday, March 7th, 2019, at 5:00 pm ET to discuss its financial results for the fourth quarter of 2018 in conjunction with the filing of its annual report on Form 10-K. Jed Latkin, Chief Executive Officer, and Erika Gibson, Director, Finance and ...
-$0.02 per share